Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAlyssa M. KanegaiAFAyesha FraserHSHrishikesh K. Srinagesh

Discussion

Loading...

Member takes

Overview

Phase 1 trials demonstrate enhanced survival and antitumor activity of allogeneic CAR19/22 in high-risk B-ALL patients.

Key Points

  • This research aims to evaluate the efficacy of allogeneic CAR19/22 compared to autologous CAR19/22 in high-risk adult B-ALL.
  • Conducted two Phase 1 trials for adult patients with high-risk B-ALL using CAR-T cells.
  • Compared toxicity and efficacy between autologous and allogeneic CAR19/22 recipients.
  • Used a bivalent lentiviral vector to express CAR19/22 in engineered CAR-T cells.
  • Allogeneic CAR19/22 resulted in superior survival rates compared to autologous CAR19/22.
  • Eighteen-month progression-free survival was 100% in the allo cohort versus 38.5% in the auto cohort.
  • CAR persistence was significantly longer in the allogeneic group compared to the autologous group.

Cite This Study

Kanegai et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e194https://doi.org/10.1182/blood-2025-514
View Full Paper
Ask AI
Bookmark
Share